Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma.
PETCT
PTCL
TLG
TMTV
interim PET
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
04
10
2019
revised:
20
05
2020
accepted:
24
05
2020
pubmed:
20
6
2020
medline:
3
6
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Peripheral T-cell lymphoma (PTCL) represents a heterogeneous and rare subgroup of aggressive lymphomas that generally demonstrate poor clinical outcomes with conventional treatment. Since the prognosis of PTCL is heterogeneous, more accurate risk assessment, and risk-adapted treatment strategies are required. In this study, we examined whether interim positron emission tomography (iPET)-computed tomography (PET/CT) results can be combined with baseline volume-based metabolic assessments including total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) for risk stratification in PTCL. The data of 63 patients with nodal PTCL, who had analyzable baseline PET/CT and iPET, were retrospectively reviewed. We calculated the baseline TMTV and TLG values. All iPET responses were analyzed using the Deauville 5-point scale. On univariate analysis, a prognostic index for PTCL (PIT) higher than 2 (hazard ratio [HR], 2.03; P = .026), high TMTV (>389 cm In summary, TLG combined with iPET predicted survival in PTCL more accurately. This information may help in the development of risk-adapted treatment strategies for PTCL.
Sections du résumé
BACKGROUND
Peripheral T-cell lymphoma (PTCL) represents a heterogeneous and rare subgroup of aggressive lymphomas that generally demonstrate poor clinical outcomes with conventional treatment. Since the prognosis of PTCL is heterogeneous, more accurate risk assessment, and risk-adapted treatment strategies are required. In this study, we examined whether interim positron emission tomography (iPET)-computed tomography (PET/CT) results can be combined with baseline volume-based metabolic assessments including total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) for risk stratification in PTCL.
METHODS
The data of 63 patients with nodal PTCL, who had analyzable baseline PET/CT and iPET, were retrospectively reviewed. We calculated the baseline TMTV and TLG values. All iPET responses were analyzed using the Deauville 5-point scale.
RESULTS
On univariate analysis, a prognostic index for PTCL (PIT) higher than 2 (hazard ratio [HR], 2.03; P = .026), high TMTV (>389 cm
CONCLUSIONS
In summary, TLG combined with iPET predicted survival in PTCL more accurately. This information may help in the development of risk-adapted treatment strategies for PTCL.
Identifiants
pubmed: 32558387
doi: 10.1002/cam4.3226
pmc: PMC7402824
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5509-5518Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Hematology Am Soc Hematol Educ Program. 2011;2011:515-24
pubmed: 22160083
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):4-12
pubmed: 21894546
Radiology. 2012 Aug;264(2):559-66
pubmed: 22692034
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):65-79
pubmed: 30141066
PLoS One. 2019 Jan 9;14(1):e0210224
pubmed: 30625203
Cancer. 2013 Mar 15;119(6):1195-202
pubmed: 23212736
J Clin Oncol. 2012 Dec 10;30(35):4317-22
pubmed: 23109699
Blood. 2015 Aug 20;126(8):950-6
pubmed: 26089397
PLoS One. 2014 Aug 27;9(8):e105682
pubmed: 25162396
Blood. 2004 Apr 1;103(7):2474-9
pubmed: 14645001
Int J Hematol. 2014 Mar;99(3):249-62
pubmed: 24510453
Blood Cancer J. 2016 Feb 12;6:e395
pubmed: 26871713
Blood. 2018 Mar 29;131(13):1456-1463
pubmed: 29437590
Cancer Med. 2020 Aug;9(15):5509-5518
pubmed: 32558387
Clin Nucl Med. 2019 May;44(5):e336-e341
pubmed: 30889000
J Clin Oncol. 2008 Sep 1;26(25):4124-30
pubmed: 18626005
Leukemia. 2013 Jun;27(6):1394-7
pubmed: 23183430
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2014 May 8;123(19):2915-23
pubmed: 24632715
J Nucl Med. 2018 Apr;59(4):589-595
pubmed: 28864629
N Engl J Med. 2015 Apr 23;372(17):1598-607
pubmed: 25901426
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Blood. 2019 Apr 11;133(15):1664-1676
pubmed: 30782609
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-19
pubmed: 26902371
Ann Oncol. 2018 Mar 1;29(3):715-723
pubmed: 29253087
Sci Rep. 2017 Jan 24;7:41057
pubmed: 28117395
Ann Oncol. 2016 Apr;27(4):719-24
pubmed: 26787236
Blood Adv. 2019 Jan 22;3(2):187-197
pubmed: 30670535
Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1836-42
pubmed: 23880967
Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):623-33
pubmed: 25573631